STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers clinical trials

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

This study looks at new eye drops, STN1013800, for droopy eyelids (blepharoptosis). It compares them to a dummy medicine to see if they safely and effectively lift the eyelids. Around 234 adults will take part, using the drops twice daily for 6 weeks.